{"disease":{"id":"metastatic-prostate-carcinoma","name":"Metastatic Prostate Carcinoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":11,"pipeline_drug_count":0,"trial_count":9},"drugs":{"marketed":[{"drug_id":"jevtana","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jevtana","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"Tubulin beta","drug_class":"","quality_score":null,"revenue":"300","mechanism":""},{"drug_id":"cabazitaxel","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jevtana Kit","generic_name":"cabazitaxel","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"Microtubule Inhibitor","quality_score":80,"revenue":"300","mechanism":"Cabazitaxel works by binding to tubulin beta, disrupting microtubule formation and preventing cancer cell division."},{"drug_id":"nilutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nilandron","generic_name":"NILUTAMIDE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"casodex","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Casodex","company_name":"University Health Network, Toronto","drug_phase":"discontinued","molecular_target":"Cytochrome P450 2C19, Androgen receptor, Androgen receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"mitoxantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"estring","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"estradiol-cypionate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bicalutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Casodex","generic_name":"bicalutamide","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Casodex works by blocking the androgen receptor, a protein that helps prostate cancer cells grow."},{"drug_id":"estradiol-valerate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"mitozantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"estradiol","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07484971","title":"Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Société Algérienne de Formation et Recherche en Oncologie","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07200830","title":"Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1524,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06931340","title":"Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1260,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT04050215","title":"68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":937,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04423211","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":804,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06422455","title":"Access to Genetic Testing in Underserved Patients With Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03503097","title":"Genetic Testing for Men With Metastatic Prostate Cancer","phase":"","overall_status":"TERMINATED","enrollment_count":799,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT04446117","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":575,"lead_sponsor_name":"Exelixis","has_results":true},{"nct_id":"NCT00942331","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04833517","title":"Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Universität des Saarlandes","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04447703","title":"Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":346,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03972657","title":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02740985","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT03419234","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":223,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT05573789","title":"Tumor Molecular Profiling in Patients With Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05045066","title":"Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05869682","title":"Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05054296","title":"Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05707468","title":"Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT02691975","title":"A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":197,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT02703623","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":196,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05053152","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":194,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT03217747","title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":173,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01505868","title":"Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05547386","title":"68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":163,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT06674863","title":"Addressing Health Literacy With a Tailored Survivorship Care Plan","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT06850545","title":"Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03317392","title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04777071","title":"An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":141,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04400656","title":"PROState Pathway Embedded Comparative Trial","phase":"","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT06244004","title":"FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT04592237","title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06205316","title":"SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07268794","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06369610","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04586543","title":"Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"László Mangel","has_results":false},{"nct_id":"NCT07150715","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":107,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04031378","title":"Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Fundacao Champalimaud","has_results":false},{"nct_id":"NCT04049747","title":"Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Imperial College London","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}